Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

Diego Kauffmann-Guerrero, Rudolf Maria Huber Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, German...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kauffmann-Guerrero D, Huber RM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	sclc chemotherapy lurbinectedin orphan drug Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ec7e22730186457e9bbe75d631e22ff1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec7e22730186457e9bbe75d631e22ff1
record_format	dspace
spelling	oai:doaj.org-article:ec7e22730186457e9bbe75d631e22ff12021-12-02T13:16:17ZOrphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin1179-2728https://doaj.org/article/ec7e22730186457e9bbe75d631e22ff12020-03-01T00:00:00Zhttps://www.dovepress.com/orphan-drugs-in-development-for-the-treatment-of-small-cell-lung-cance-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Diego Kauffmann-Guerrero, Rudolf Maria Huber Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, GermanyCorrespondence: Diego Kauffmann-GuerreroHospital of the University of Munich (LMU), Ziemssenstraße 1, Munich 80336, GermanyTel +49-89-4400-52187Email KauffmannGuerrero@med.uni-muenchen.deAbstract: Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second line treatment has been achieved in the field of SCLC. Lurbinectedin, a novel RNA-polymerase II inhibitor has shown promising results in pretreated SCLC patients as single agent and in combination with other chemotherapeutic drugs leading to an orphan drug designation from the FDA. This article reviews the current data on this emerging substance and its impact on the treatment of SCLC.Keywords: SCLC, chemotherapy, lurbinectedin, orphan drugKauffmann-Guerrero DHuber RMDove Medical Pressarticlesclcchemotherapylurbinectedinorphan drugNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 27-31 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	sclc chemotherapy lurbinectedin orphan drug Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	sclc chemotherapy lurbinectedin orphan drug Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kauffmann-Guerrero D Huber RM Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
description	Diego Kauffmann-Guerrero, Rudolf Maria Huber Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, GermanyCorrespondence: Diego Kauffmann-GuerreroHospital of the University of Munich (LMU), Ziemssenstraße 1, Munich 80336, GermanyTel +49-89-4400-52187Email KauffmannGuerrero@med.uni-muenchen.deAbstract: Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second line treatment has been achieved in the field of SCLC. Lurbinectedin, a novel RNA-polymerase II inhibitor has shown promising results in pretreated SCLC patients as single agent and in combination with other chemotherapeutic drugs leading to an orphan drug designation from the FDA. This article reviews the current data on this emerging substance and its impact on the treatment of SCLC.Keywords: SCLC, chemotherapy, lurbinectedin, orphan drug
format	article
author	Kauffmann-Guerrero D Huber RM
author_facet	Kauffmann-Guerrero D Huber RM
author_sort	Kauffmann-Guerrero D
title	Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
title_short	Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
title_full	Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
title_fullStr	Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
title_full_unstemmed	Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
title_sort	orphan drugs in development for the treatment of small-cell lung cancer: emerging data on lurbinectedin
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/ec7e22730186457e9bbe75d631e22ff1
work_keys_str_mv	AT kauffmannguerrerod orphandrugsindevelopmentforthetreatmentofsmallcelllungcanceremergingdataonlurbinectedin AT huberrm orphandrugsindevelopmentforthetreatmentofsmallcelllungcanceremergingdataonlurbinectedin
_version_	1718393364330577920

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

Ejemplares similares